DRESS Syndrome - Initial Management

Key Points

• DRESS commonly begins weeks after a new medication and can worsen after the drug is stopped.
• Fever, facial edema, eosinophilia or atypical lymphocytes, and internal-organ injury are major clues.
• Stop the suspected culprit and other nonessential recent drugs immediately.
• Check for clinically silent liver and kidney injury even when the skin eruption appears dominant.
• Systemic corticosteroids are commonly used for significant internal-organ disease and generally require a slow taper.
• Myocarditis is uncommon but high risk and should be considered with disproportionate tachycardia, chest symptoms, or cardiac biomarker elevation.
• Patients require follow-up for relapse and delayed autoimmune complications.

Algorithm

1. Construct a complete medication timeline covering the prior two months or longer when appropriate.
2. Stop plausible culprit medications and nonessential recently started agents.
3. Examine for facial edema, lymphadenopathy, mucosal disease, blistering, skin pain, and signs of organ dysfunction.
4. Obtain CBC with differential, liver tests, creatinine, electrolytes, and urinalysis; add organ-specific testing as indicated.
5. Apply a structured diagnostic framework such as RegiSCAR and exclude infection and other SCAR syndromes.
6. Use topical therapy for mild skin-predominant disease and systemic corticosteroids for significant organ involvement.
7. Admit severe disease and involve dermatology plus the relevant organ specialists.
8. Trend laboratory abnormalities and taper therapy slowly with outpatient monitoring.

Clinical Synopsis & Reasoning

Drug reaction with eosinophilia and systemic symptoms usually begins two to eight weeks after a new medication, although timing varies with re-exposure and specific drugs. The eruption is often widespread and morbilliform with facial edema, fever, lymphadenopathy, eosinophilia or atypical lymphocytes, and injury to one or more organs. Hepatitis is common, but nephritis, pneumonitis, myocarditis, encephalitis, thyroiditis, and other inflammatory complications can occur. The syndrome may continue to evolve after the drug is stopped, which distinguishes it from many uncomplicated exanthematous drug eruptions.

Diagnosis is clinical and is strengthened by a structured system such as RegiSCAR. The medication timeline is central. High-risk culprits include aromatic antiseizure drugs, allopurinol, sulfonamide antibiotics, vancomycin, minocycline, dapsone, and several antiretroviral or targeted agents. A patient with mucosal erosion, skin pain, blistering, or epidermal detachment requires evaluation for Stevens-Johnson syndrome or toxic epidermal necrolysis instead. Pustules suggest AGEP, and shock or a focal infection may indicate an infectious mimic.

Organ injury may be clinically silent at presentation. Obtain blood count with differential, metabolic panel, liver tests, urinalysis, and additional testing guided by symptoms. Troponin and ECG are appropriate with chest pain, dyspnea, tachycardia out of proportion, or concern for myocarditis. DRESS can relapse during steroid taper or after exposure to an unrelated medication, so diagnosis initiates a prolonged follow-up period rather than ending at discharge.

Treatment Strategy & Disposition

Stop the culprit drug and all nonessential new medications immediately. Document the suspected medication prominently and avoid related agents when cross-reactivity is clinically relevant. Supportive treatment includes emollients, topical corticosteroids, antihistamines for pruritus, fluid and electrolyte management, and treatment of secondary infection only when infection is actually present.

Patients with significant hepatitis, nephritis, pneumonitis, myocarditis, or other major organ involvement generally require systemic corticosteroid therapy, commonly prednisone-equivalent dosing around 0.5 to 1 mg/kg/day with a slow taper tailored to response and organ severity. Life-threatening organ disease may require IV corticosteroids and subspecialty management. A rapid taper can precipitate relapse. Severe refractory disease has been treated with other immunomodulators in specialist settings, but evidence is less robust and therapy should be individualized.

Admit patients with hemodynamic instability, extensive eruption plus systemic illness, important organ injury, inability to maintain hydration, or concern for a competing severe cutaneous adverse reaction. Trend CBC, creatinine, liver tests, and affected-organ markers until clearly improving. Long-term follow-up should include surveillance for delayed autoimmune sequelae such as thyroid disease and diabetes when clinically appropriate.

Epidemiology / Risk Factors

• DRESS is uncommon but carries clinically important mortality, largely from severe organ involvement.
• Latency is typically longer than for simple exanthematous drug eruptions.
• Anticonvulsants, allopurinol, antibiotics, and selected anti-infective agents are frequent triggers.
• Genetic risk varies by ancestry and drug, including established HLA associations for certain medications.

Investigations

Common Culprit Drugs

Pharmacology

Prognosis / Complications

• Most patients recover after withdrawal of the culprit and appropriate treatment, but symptoms may persist for weeks to months.
• Severe hepatitis, myocarditis, and multi-organ failure account for much of the mortality.
• Relapse can occur during rapid corticosteroid taper or after introduction of new drugs.
• Delayed autoimmune thyroid disease and other autoimmune sequelae may appear months after the acute episode.

Patient Education / Counseling

• Explain that this is a systemic drug reaction, not simply a skin allergy.
• Provide the exact culprit or suspected culprit medication in written discharge instructions.
• Advise the patient not to restart the drug unless a specialist later determines it is safe.
• Review warning signs including jaundice, dyspnea, chest pain, decreasing urine output, fever recurrence, or worsening rash.
• Emphasize the need for scheduled laboratory follow-up even after the skin begins to improve.

Notes

DRESS is a timeline diagnosis as much as a morphology diagnosis. A careful list of every prescription, over-the-counter product, supplement, intermittent antibiotic, and recent hospital medication often identifies a culprit that is missed when only the active medication list is reviewed.

The emergency priority is not to identify the single culprit with perfect certainty before acting. Stop the most plausible high-risk drugs, evaluate organ injury, and avoid unnecessary new medications while dermatology and other specialists refine causality.

References

1. American Academy of Dermatology resources on severe cutaneous adverse reactions — Link
2. RegiSCAR severe cutaneous adverse reaction framework — Link